Mauna Kea Technologies

Capital/Financing Update • Jan 11, 2016

HALF-YEARLY REPORT ON THE LIQUIDITY CONTRACT WITH GILBERT DUPONT

PARIS, January 11,2016 /PRNewswire/ --

Pursuant to the liquidity contract entrusted to Gilbert Dupont, on 31 December 2015 the following assets appeared on the liquidity account:

• Number of shares: 36,363
• Cash balance of the liquidity account: €64 689,01

As a reminder, at the time of the last Half-Yearly report on 30 June 2015, the following resources were booked to the liquidity account:

- Number of shares: 22,911

- Cash balance of the liquidity account: €106,566.86

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on protecting patients' lives while enabling physicians and surgeons to make better decisions thanks to direct visualization at the cellular level. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit http://www.maunakeatech.com.

Mauna Kea Technologies

Investors relations US

Sebastien Cadet

Global Marketing Director and OEM Leader

sebastienc@maunakeatech.com

NewCap.

Investor Relations Europe

Florent Alba

Tel: +33(0)1-44-71-94-94

maunakea@newcap.eu

This is a disclosure announcement from PR Newswire.